Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling
Metabolic landscape and sensitivity to apoptosis induction play a crucial role in acute myeloid leukemia (AML) resistance. Therefore, we investigated the effect of metformin, a medication that also acts as an inhibitor of oxidative phosphorylation (OXPHOS), and MCL-1 inhibitor S63845 in AML cell lin...
Main Authors: | Giedrė Valiulienė, Aida Vitkevičienė, Giedrė Skliutė, Veronika Borutinskaitė, Rūta Navakauskienė |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/26/8/2303 |
Similar Items
-
MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression
by: Yasuda, Yuto
Published: (2020) -
BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
by: Katja Seipel, et al.
Published: (2021-02-01) -
Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia
by: Yu-Jun Dai, et al.
Published: (2021-01-01) -
Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines
by: Siti Fairus Abdul Rahman, et al.
Published: (2020-07-01) -
Menstrual Blood-Derived Endometrial Stem Cells’ Impact for the Treatment Perspective of Female Infertility
by: Giedrė Skliutė, et al.
Published: (2021-06-01)